

Stephen A Strickland, Msci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5679400/publications.pdf>

Version: 2024-02-01

39
papers

1,928
citations

361045

20
h-index

377514

34
g-index

39
all docs

39
docs citations

39
times ranked

3327
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and treatment of therapy-related acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103607.	2.0	19
2	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	23
3	Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 927-931.	1.2	1
4	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	2.0	4
5	Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 631-640.	0.6	15
6	Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. <i>Leukemia and Lymphoma</i> , 2020, 61, 3146-3153.	0.6	11
7	The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1006-1014.	2.0	45
8	Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. <i>Haematologica</i> , 2020, 105, 1567-1574.	1.7	25
9	A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2191-2199.	0.6	4
10	SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
11	Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141). <i>Blood</i> , 2020, 136, 30-31.	0.6	0
12	Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e122-e131.	2.2	20
13	The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 180-180.	0.6	4
14	Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2643-2643.	0.6	0
15	Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 65, 67-73.	0.4	12
16	A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. <i>Cancer Discovery</i> , 2018, 8, 1566-1581.	7.7	250
17	Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML). <i>Leukemia Research</i> , 2018, 72, 92-95.	0.4	30
18	Midostaurin in Adults with Newly Diagnosed FLT3-Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy: Update from the Radius-X Midostaurin Expanded Access Program. <i>Blood</i> , 2018, 132, 4038-4038.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. <i>Blood</i> , 2018, 132, 284-284.	0.6	30
20	MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2144-2155.	0.6	26
21	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	5.1	402
22	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 926-957.	2.3	451
23	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. <i>Blood</i> , 2017, 130, 890-890.	0.6	41
24	High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. <i>Cell Reports</i> , 2016, 16, 2003-2016.	2.9	69
25	Epigenetic landscape of the <i><sc>TERT</sc></i> promoter: a potential biomarker for high risk <sc>AML</sc>/<sc>MDS</sc>. <i>British Journal of Haematology</i> , 2016, 175, 427-439.	1.2	25
26	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2016, 128, 1069-1069.	0.6	35
27	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 901-901.	0.6	42
28	Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1172-1179.	1.7	93
29	Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. <i>BMC Genomics</i> , 2015, 16, 727.	1.2	42
30	<sc>REVEAL</sc>–1, a phase 2 dose regimen optimization study of vosaroxin in older poor–risk patients with previously untreated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2015, 168, 796-805.	1.2	27
31	A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia. <i>Blood</i> , 2014, 124, 1047-1047.	0.6	5
32	T Cell Exhaustion and Downregulation of Cytotoxic NK Cells “ an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3781-3781.	0.6	11
33	Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 528-534.	0.6	9
34	Optimizing Personalized Bone Marrow Testing Using an Evidence-Based, Interdisciplinary Team Approach. <i>American Journal of Clinical Pathology</i> , 2013, 140, 643-650.	0.4	30
35	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 1096-1104.	5.1	58
36	Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy. <i>Blood</i> , 2011, 118, 2073-2073.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2010, 95, 860-863.	1.7	65
38	Hiccups: underappreciated and underrecognized. <i>The Journal of Supportive Oncology</i> , 2009, 7, 128-9.	2.3	2
39	Nucleated Cell (NC) Dose of Autologous (Auto) Marrow Graft Is Not Predictive of Engraftment after Auto-Bone Marrow Transplant (auto-BMT) Following Failed Peripheral Blood Stem Cell (PBSC) Mobilization.. <i>Blood</i> , 2006, 108, 5454-5454.	0.6	0